PolyPid Stock

PolyPid EBITDA per Share

The EBITDA per Share of PolyPid (PYPD) as of Sep 5, 2026 is -1.60 USD. In the previous year, EBITDA per Share was -3.72 USD — a change of -56.93% (higher).

EBITDA per Share

-1.60USD

YoY

-56.93%

Last updated:

EBITDA per Share of PolyPid is 2026 -1.60 USD. EBITDA per Share of PolyPid was 2025 -3.72 USD. It decreases by -56.93% higher compared to the previous year.

The PolyPid EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2017
-24.29 USD
Jan 1, 2019
-20.94 USD
Jan 1, 2020
-21.31 USD
Jan 1, 2021
-34.29 USD
Jan 1, 2022
-29.67 USD
Jan 1, 2023
-13.78 USD
Jan 1, 2024
-3.72 USD
Jan 1, 2025
-1.60 USD
The PolyPid EBITDA per Share history
YEAREBITDA per ShareYoY
-1.60USD-56.93%
-3.72USD-73.02%
-13.78USD-53.57%
-29.67USD-13.46%
-34.29USD+60.93%
-21.31USD+1.76%
-20.94USD-13.79%
-24.29USD
Access this data via the Eulerpool API

PolyPid Stock analysis

What does PolyPid do? PolyPid Ltd is an innovative, emerging company in the field of biomedical technology based in Israel. The company was founded in 2008 and has since gained continuous recognition and growth. PolyPid's core business is the development and manufacturing of implantable polymer systems that contribute to wound healing. These polymer systems are specifically introduced into the affected area of the body and continuously release active substances to prevent infections and promote natural healing processes. PolyPid's business model is focused on effectively solving patients' problems. The company has developed a wide range of products and technologies that specifically target various medical applications. These include orthopedics, traumatology, urology, and gynecology. For orthopedics, PolyPid provides various products and technologies that can be used in knee and hip joint surgeries. These include antibiotic-releasing implants to prevent infections and resorbable bone fillers that allow for faster and more effective wound healing. In the field of traumatology, PolyPid manufactures polymer systems that are used in the treatment of bone fractures or other traumas. Here again, the polymer systems ensure continuous release of active substances to prevent infections and promote natural healing processes. PolyPid also offers innovative solutions for urology. Specifically, products are developed to combat urinary tract infections and promote faster wound healing after urological surgeries. For gynecology, PolyPid offers polymer systems that can be used particularly in the postoperative phase to prevent infections and achieve faster wound healing. PolyPid has earned an excellent reputation in the industry in recent years due to its consistent focus on innovation and quality. To continually improve their products, the company invests heavily in research and development and maintains close contact with medical institutions and professionals worldwide. PolyPid is an important partner in the field of biomedical technology and has already received numerous awards for its groundbreaking products and developments. Thanks to its focus on quality, reliability, and innovation, the company will continue to play a key role in the biomedical technology market. PolyPid is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PolyPid stock

EBITDA per Share of PolyPid is -1.60 USD in 2026.

EBITDA per Share of PolyPid changed from -3.72 USD to -1.60 USD, representing a -56.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share PolyPid since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

Income Statement — PolyPid

All Key Metrics — PolyPid